Home/Pipeline/CTX131

CTX131

Solid Tumors

PreclinicalResearch

Key Facts

Indication

Solid Tumors

Phase

Preclinical

Status

Research

Company

CRISPR Therapeutics

About CRISPR Therapeutics

CRISPR Therapeutics is a pioneering biopharmaceutical company dedicated to discovering, developing, and commercializing curative gene-editing treatments. Founded by CRISPR gene-editing pioneers, the company leverages its proprietary CRISPR/Cas9 platform to create a diverse pipeline targeting hemoglobinopathies, immuno-oncology, regenerative medicine, and in vivo diseases. Its landmark achievement is the approval of CASGEVY, the world's first CRISPR/Cas9 gene-edited therapy, marking a new era in medicine and validating its platform's potential. The company collaborates with Vertex Pharmaceuticals and Bayer to accelerate development and commercialization across multiple therapeutic areas.

View full company profile

Therapeutic Areas

Hemoglobinopathies Oncology Regenerative Medicine Cardiovascular Disease Central Nervous System (CNS) Diseases Genetic Diseases

Other Solid Tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
SHR-1316	Jiangsu Hengrui Medicine	Phase 1/2	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
Bispecific Antibody	Akeso	Phase 1/2	Active
CSPC-DM02	CSPC Pharmaceutical Group Limited	Phase 2	Active